Propanc Biopharma shares surge 37.64% premarket as PRP therapy advances to Phase 1b trial for pancreatic cancer.

Propanc Biopharma surged 37.64% in premarket trading following the announcement of its lead proenzyme therapy PRP, designed to target cancer stem cells and inhibit metastasis in pancreatic cancer. The therapy, which demonstrated over 85% tumor growth inhibition in preclinical studies, received FDA Orphan Drug Designation in 2017 and is set to enter a Phase 1b First-In-Human trial in 2026, involving 30–40 patients with advanced solid tumors. The company emphasized PRP’s differentiated mechanism, potential to reduce chemotherapy toxicity, and alignment with a rapidly growing pancreatic cancer market projected to reach $10.25 billion by 2034. Strengthening its IP portfolio and positioning as a potential alternative to current therapies, Propanc highlighted the unmet need in metastatic cancers and the commercial opportunity in treating 80% of cancers classified as solid tumors. The bullish move reflects investor optimism over PRP’s clinical and commercial potential.